Document the peer-reviewed evidence for MDMA-assisted psychotherapy in treatment-resistant PTSD, the regulatory history of MDMA's Schedule I classification, and what the delay in clinical translation represents in human cost.

Systematic review of MDMA-assisted therapy clinical literature (PubMed, Nature Medicine), DEA scheduling history primary documents, FDA Breakthrough Therapy designation records, and VA veteran PTSD and suicide data.

The Evidence

I will start with the clinical data before the policy history, because the data is strong enough to stand on its own.

Mitchell et al. 0001). Remission rate: 46% versus 21%. This is not a pilot study. This is a multi-site Phase III trial published in Nature Medicine. The effect size is among the largest ever observed in a psychiatric intervention trial for PTSD.

The MAPS (Multidisciplinary Association for Psychedelic Studies) Phase III trial (Mithoefer et al., 2018, also Nature Medicine) showed similar results in a separate cohort. The FDA granted MDMA-assisted therapy Breakthrough Therapy designation in 2017, which is reserved for treatments with substantial improvement over available therapy on a serious or life-threatening condition.

Treatment-resistant PTSD — the population in these trials — does not respond to SSRIs, the standard of care. The veteran PTSD epidemic is not a mystery. It is a condition with a documented 10-22 suicide per day death rate among veterans (VA data, various years), inadequate treatment options, and a therapy that Phase III trials show works in 67% of treatment-resistant cases that currently have no effective option.

The Regulatory History

MDMA was first synthesized by Merck in 1912. It was rediscovered by chemist Alexander Shulgin in 1976 and introduced to psychotherapists as a therapeutic tool in the late 1970s. By 1985, an estimated 500,000 doses had been administered in therapeutic contexts. No fatalities were directly attributed to therapeutic MDMA in this period.

In 1985, the DEA placed MDMA on an emergency Schedule I classification — defined as no accepted medical use and high abuse potential. The administrative law judge appointed to review the scheduling (Judge Francis Young) recommended in 1986 that MDMA be placed in Schedule III to permit medical use. The DEA overruled its own administrative law judge and maintained Schedule I. Young's ruling explicitly stated that the evidence for therapeutic use was sufficient to meet the legal standard.

Schedule I classification does not prevent research but makes it extraordinarily expensive and slow. Researchers must obtain DEA Schedule I researcher registration (a separate, lengthy process), source the drug from the National Institute on Drug Abuse's limited supply program, and navigate institutional review processes designed for conventional drugs. The MAPS Phase III trials took 35 years from the initial scheduling to complete.

What 35 Years Costs

The VA estimates that 20 veterans per day died by suicide in 2022. , JAMA, 2005). PTSD is a significant risk factor for suicide. I am not claiming that MDMA would have saved every veteran who died by suicide in the past 35 years.

I am claiming that a therapy with a 67% response rate in treatment-resistant PTSD, which has been available as a molecule since 1976 and demonstrated therapeutic potential since the early 1980s, has not been available to the 500,000 veterans currently diagnosed with PTSD because a bureaucratic agency overruled its own expert and placed it in the most restrictive possible classification.

The DEA's 1985 emergency scheduling decision was driven primarily by recreational use concerns — the drug was appearing in nightclubs and the DEA acted on reports of neurotoxicity from animal studies using much higher doses than therapeutic protocols. The neurotoxicity finding (Ricaurte et al., 1985) used doses 10-20x the therapeutic range. This distinction was available in 1985. It was not used.

I want to be fair to the DEA. Scheduling decisions are difficult. Abuse potential is a real concern. The recreational context does produce harms. But the Schedule I classification — which formally asserts 'no accepted medical use' — was maintained for 35 years after a body of peer-reviewed evidence established clear therapeutic use. The administrative law judge said so in 1986. It took until 2017 for the FDA to formally acknowledge what the judge said in 1986.

What Happens Now

The FDA's MDMA-assisted therapy review resulted in a rejection in August 2024, citing concerns about trial methodology — specifically, the inability to blind participants to whether they received MDMA (because the drug has perceptible effects). The FDA asked for an additional trial. MAPS has challenged the methodology concern, arguing that functional unblinding is inherent to any psychedelic therapy trial design and cannot be resolved without restarting the field from scratch.

The FDA's methodology concern is legitimate and also convenient. It applies to every psychedelic therapy trial ever conducted or conceivable. A regulatory standard that cannot in principle be met by any psychedelic therapy trial is not a standard — it is a prohibition with extra steps. I expect this observation to be contested. I have the primary documents.

The FDA's own Breakthrough Therapy designation for MDMA-assisted therapy in 2017 acknowledged that existing evidence substantially exceeded available alternatives. The August 2024 rejection on methodology grounds is difficult to reconcile with that 2017 finding without concluding that something other than pure scientific assessment is operating.